ClinConnect ClinConnect Logo
Search / Trial NCT05534386

A Self-management Based Survivorship Intervention for Chinese Cancer Survivors

Launched by THE UNIVERSITY OF HONG KONG · Sep 6, 2022

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Physical Symptom Distress Weight Management Self Efficacy In Managing Cancer Health Related Quality Of Life Survivorship Intervention Sequential Multiple Assessment Randomized Controlled Trial Psychooncology

ClinConnect Summary

This clinical trial is looking at a special program designed to help Chinese cancer survivors manage their health after treatment. The goal is to see if this program can reduce physical symptoms, help with weight management, boost confidence in handling health issues, and improve overall quality of life for patients who have recently completed their cancer treatment. The study is currently recruiting participants aged 65 to 74 who speak Cantonese or Mandarin and have been diagnosed with a curable type of cancer.

To join the study, participants should have finished their main cancer treatments within the last six months. However, those with metastatic cancer, which means their cancer has spread to other parts of the body, are not eligible. If you participate, you can expect to engage in this self-management program and share your experiences, which will help researchers understand how to better support cancer survivors in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Cantonese- or Mandarin-speaking Chinese patients diagnosed curable cancer
  • have completed primary and adjuvant treatment within the past six months
  • Exclusion Criteria:
  • Patients diagnosed with metastatic cancer

About The University Of Hong Kong

The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.

Locations

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Wendy Wing Tak Lam, PhD

Principal Investigator

School of Public Health, The University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials